20154-03-4 | Page 5 of 14 | pyrazoles-derivatives

Lyu, Jiyuan’s team published research in Journal of Organic Chemistry in 2020 | CAS: 20154-03-4

3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4) belongs to pyrazoles. The application of pyrazole derivatives in the development of anticancer agents has been thoroughly investigated and verified. Moreover, the medicinal features of a number of natural products incorporating pyrazole moiety such as pyrazofurin, pyrazofurin B, pyrazole-3(5)-carboxylic acid and 4-methylpyrazole-3(5)-carboxylic acid have been reported.Formula: C4H3F3N2

《Preparation of Chiral Photosensitive Organocatalysts and Their Application for the Enantioselective Synthesis of 1,2-Diamines》 was published in Journal of Organic Chemistry in 2020. These research results belong to Lyu, Jiyuan; Claraz, Aurelie; Vitale, Maxime R.; Allain, Clemence; Masson, Geraldine. Formula: C4H3F3N2 The article mentions the following:

Chiral phosphoric acid based organocatalysis and visible-light photocatalysis have both emerged as promising technologies for the sustainable production of fine chems. In this context, we have envisioned the design and the synthesis of a new class of chimeric catalytic entities that would feature both catalytic capabilities. Given their multitask nature, such catalysts would be particularly attractive for the development of new catalytic transformations, tandem processes in particular. Toward this goal, several BINOL-based chiral phosphoric acid backbones presenting one or two visible-light-sensitive thioxanthone moieties have been prepared and studied. The utility of these new photoactive chiral organocatalysts is then demonstrated in the enantioselective tandem three-component electrophilic amination of enecarbamates. Of note, the C1-sym. organo/photocatalyst has shown a better catalytic activity than those presenting a C2 symmetry. After reading the article, we found that the author used 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4Formula: C4H3F3N2)

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Sandoval, Angel’s team published research in Biochemical Pharmacology in 2012 | CAS: 20154-03-4

In 2012,Sandoval, Angel; Chokshi, Aalap; Jesch, Elliot D.; Black, Paul N.; DiRusso, Concetta C. published 《Identification and characterization of small compound inhibitors of human FATP2 [Erratum to document cited in CA152:421565]》.Biochemical Pharmacology published the findings.Reference of 3-(Trifluoromethyl)-1H-pyrazole The information in the text is summarized as follows:

On page 997, Compound CB-5 in Table 3B contained a structure error; the corrected structure is given. In the experimental materials used by the author, we found 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4Reference of 3-(Trifluoromethyl)-1H-pyrazole)

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Sandoval, Angel’s team published research in Biochemical Pharmacology in 2010 | CAS: 20154-03-4

In 2010,Sandoval, Angel; Chokshi, Aalap; Jesch, Elliot D.; Black, Paul N.; Di Russo, Concetta C. published 《Identification and characterization of small compound inhibitors of human FATP2》.Biochemical Pharmacology published the findings.Application In Synthesis of 3-(Trifluoromethyl)-1H-pyrazole The information in the text is summarized as follows:

Fatty acid transport proteins (FATPs) are bifunctional proteins, which transport long chain fatty acids into cells and activate very long chain fatty acids by esterification with CoA. In an effort to understand the linkage between cellular fatty acid transport and the pathol. associated with excessive accumulation of exogenous fatty acids, we targeted FATP-mediated fatty acid transport in a high throughput screen of more than 100,000 small diverse chem. compounds in yeast expressing human FATP2 (hsFATP2). Compounds were selected for their ability to depress the transport of the fluorescent long chain fatty acid analog, C1-BODIPY-C12. Among 234 hits identified in the primary screen, 5 compounds, each representative of a structural class, were further characterized in the human Caco-2 and HepG2 cell lines, each of which normally expresses FATP2, and in 3T3-L1 adipocytes, which do not. These compounds were effective in inhibiting uptake with IC50s in the low micromolar range in both Caco-2 and HepG2 cells. Inhibition of transport was highly specific for fatty acids and there were no effects of these compounds on cell viability, trans-epithelial elec. resistance, glucose transport, or long chain acyl-CoA synthetase activity. The compounds were less effective when tested in 3T3-L1 adipocytes suggesting selectivity of inhibition. These results suggest fatty acid transport can be inhibited in a FATP-specific manner without causing cellular toxicity. In addition to this study using 3-(Trifluoromethyl)-1H-pyrazole, there are many other studies that have used 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4Application In Synthesis of 3-(Trifluoromethyl)-1H-pyrazole) was used in this study.

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

He, Yali’s team published research in Journal of Medicinal Chemistry in 2020 | CAS: 20154-03-4

3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4) belongs to pyrazoles. Pyrazole derivatives have been reported to exhibit a wide range of applications in medicinal chemistry and pharmacology. A large number of drugs incorporating pyrazole structure have been utilized as partial agonists for nicotinic acid receptors, antidepressants, antimicrobial agents, antiviral agents, and antifungal agents solely or along with the combination of other structural motifs.HPLC of Formula: 20154-03-4

HPLC of Formula: 20154-03-4In 2020 ,《Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer》 appeared in Journal of Medicinal Chemistry. The author of the article were He, Yali; Hwang, Dong-Jin; Ponnusamy, Suriyan; Thiyagarajan, Thirumagal; Mohler, Michael L.; Narayanan, Ramesh; Miller, Duane D.. The article conveys some information:

We report herein the design, synthesis, and pharmacol. characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacol. evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens’ general pharmacophore allowed the development of a new scaffold of small mols. with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 and UT-34. Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. I was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer. After reading the article, we found that the author used 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4HPLC of Formula: 20154-03-4)

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Shim, Heesung’s team published research in Frontiers in Pharmacology in 2019 | CAS: 20154-03-4

In 2019,Frontiers in Pharmacology included an article by Shim, Heesung; Brown, Brandon M.; Singh, Latika; Singh, Vikrant; Fettinger, James C.; Yarov-Yarovoy, Vladimir; Wulff, Heike. Name: 3-(Trifluoromethyl)-1H-pyrazole. The article was titled 《The trials and tribulations of structure assisted design of KCa channel activators》. The information in the text is summarized as follows:

Calcium-activated K+ channels constitute attractive targets for the treatment of neurol. and cardiovascular diseases. To explain why certain 2-aminobenzothiazole/oxazole-type KCa activators (SKAs) are KCa3.1 selective we previously generated homol. models of the C-terminal calmodulin-binding domain (CaM-BD) of KCa3.1 and KCa2.3 in complex with CaM using Rosetta modeling software. We here attempted to employ this atomistic level understanding of KCa activator binding to switch selectivity around and design KCa2.2 selective activators as potential anticonvulsants. In this structure-based drug design approach we used RosettaLigand docking and carefully compared the binding poses of various SKA compounds in the KCa2.2 and KCa3.1 CaM-BD/CaM interface pocket. Based on differences between residues in the KCa2.2 and KCa.3.1 models we virtually designed 168 new SKA compounds The compounds that were predicted to be both potent and KCa2.2 selective were synthesized, and their activity and selectivity tested by manual or automated electrophysiol. However, we failed to identify any KCa2.2 selective compounds Based on the full-length KCa3.1 structure it was recently demonstrated that the C-terminal crystal dimer was an artifact and suggested that the “”real”” binding pocket for the KCa activators is located at the S4-S5 linker. We here confirmed this structural hypothesis through mutagenesis and now offer a new, corrected binding site model for the SKA-type KCa channel activators. SKA-111 (5-methylnaphtho[1,2-d]thiazol-2-amine) is binding in the interface between the CaM N-lobe and the S4-S5 linker where it makes van der Waals contacts with S181 and L185 in the S45A helix of KCa3.1. The experimental part of the paper was very detailed, including the reaction process of 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4Name: 3-(Trifluoromethyl)-1H-pyrazole)

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Lv, Shuaipeng’s team published research in Communications Chemistry in 2019 | CAS: 20154-03-4

《Lewis base-catalyzed intermolecular triazene alkyne cycloaddition for late-stage functionalization and scaffold diversification》 was written by Lv, Shuaipeng; Zhou, Hui; Yu, Xin; Xu, Yue; Zhu, Huijuan; Wang, Min; Liu, Haitao; Dai, Ziru; Sun, Guibo; Gong, Xiaojie; Sun, Xiaobo; Wang, Lei. Category: pyrazoles-derivativesThis research focused ontriazene 3 Trifluoromethylpyrazole cycloaddition Lewis base platelet aggregation inhibitor. The article conveys some information:

3-Trifluoromethylpyrazole and its derivatives are of major interest to both the agrochem. and pharmaceutical industry for their diverse biol. activities. Reported routes for the synthesis of 3-trifluoromethylpyrazoles are hindered by poor regioselectivity and limited scope of application. Here we report a directed Lewis base catalyzed intermol. triazene-alkyne cycloaddition It is featured that the combination of 1,8-diazabicyclo[5.4.0]undec-7-ene and 2,2,2-trifluorodiazoethane produces reactive triazene intermediates, which readily participate in cycloaddition reactions with terminal/internal alkynes, thus assembling densely substituted 3-trifluoromethylpyrazole scaffolds with environmental friendliness and operational simplicity. Synthetic utility of the protocol is highlighted by late-stage functionalization and scaffolds diversification. The practical value is also emphasized in potential platelet aggregation inhibitor synthesis. In addition to this study using 3-(Trifluoromethyl)-1H-pyrazole, there are many other studies that have used 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4Category: pyrazoles-derivatives) was used in this study.

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Greenacre, Victoria K.’s team published research in Organometallics in 2015 | CAS: 20154-03-4

Formula: C4H3F3N2In 2015 ,《Ruthenaphosphaalkenyls: synthesis, structures, and their conversion to η2-phosphaalkene complexes》 was published in Organometallics. The article was written by Greenacre, Victoria K.; Trathen, Nicola; Crossley, Ian R.. The article contains the following contents:

The ruthenaphosphaalkenyls [Ru{P:CH(SiMe2R)}Cl(CO)(PPh3)2] (R = Me, Ph, Tol) have been prepared in good yield by the facile hydroruthenation of the resp. phosphaalkynes, RMe2SiCP, with [RuHCl(CO)(PPh3)3]; all three compounds have been structurally characterized in the solid state. Complemented by DFT studies of these, and the precedent [Ru{P:CH(tBu)}Cl(CO)(PPh3)2], the phosphaalkenyl moieties have been established unequivocally to behave as one-electron donors to the coordinately unsaturated, 15-electron “”RuCl(CO)(PPh3)2″” fragment, corroborating an earlier demonstration of nucleophilic character at phosphorus within the tert-Bu system. Notwithstanding, the ruthenaphosphaalkenyls are shown to react with the nucleophiles Lipz’ (pz’ = pz, pz*, pzH,CF3, pzMe,CF3) to afford the η1,η2-chelated pyrazolylphosphaalkene complexes [Ru{η1-N:η2-P,C-P(pz’):CH(R)}(CO)(PPh3)2], which feature a three-membered metallacyclic (Ru-C-P) core. The nature of these novel compounds is discussed, alongside preliminary insight into the process by which they are formed. The results came from multiple reactions, including the reaction of 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4Formula: C4H3F3N2)

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Gaulier, Steven M.’s team published research in Tetrahedron Letters in 2012 | CAS: 20154-03-4

In 2012,Gaulier, Steven M.; McKay, Reuben; Swain, Nigel A. published 《A novel three-step synthesis of celecoxib via palladium-catalyzed direct arylation [Erratum to document cited in CA155:562830]》.Tetrahedron Letters published the findings.Category: pyrazoles-derivatives The information in the text is summarized as follows:

On page 6001, Compound 4 in Scheme 1 contained a structure error; the corrected scheme is given. The results came from multiple reactions, including the reaction of 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4Category: pyrazoles-derivatives)

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Deng, Xiaohu’s team published research in Journal of Organic Chemistry in 2011 | CAS: 20154-03-4

In 2011,Deng, Xiaohu; Roessler, Armin; Brdar, Ivana; Faessler, Roger; Wu, Jiejun; Sales, Zachary S.; Mani, Neelakandha S. published 《Direct, metal-free amination of heterocyclic amides/ureas with NH-heterocycles and N-substituted anilines in POCl3》.Journal of Organic Chemistry published the findings.Related Products of 20154-03-4 The information in the text is summarized as follows:

A POCl3-mediated, direct amination reaction of heterocyclic amides/ureas with NH-heterocycles or N-substituted anilines is described. Compared to the existing methods, this operationally simple protocol provides unique reactivity and functional group compatibility because of the metal-free, acidic reaction conditions. The yields are generally excellent. The results came from multiple reactions, including the reaction of 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4Related Products of 20154-03-4)

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Hu, Yimin’s team published research in Journal of Medicinal Chemistry in 2020 | CAS: 20154-03-4

Safety of 3-(Trifluoromethyl)-1H-pyrazoleIn 2020 ,《Discovery of Pyrido[2,3-b]indole Derivatives with Gram-Negative Activity Targeting Both DNA Gyrase and Topoisomerase IV》 appeared in Journal of Medicinal Chemistry. The author of the article were Hu, Yimin; Shi, Houguang; Zhou, Mingwei; Ren, Qingcheng; Zhu, Wei; Zhang, Weixing; Zhang, Zhiwei; Zhou, Chengang; Liu, Yongqiang; Ding, Xiao; Shen, Hong C.; Yan, S. Frank; Dey, Fabian; Wu, Waikwong; Zhai, Guanglei; Zhou, Zheng; Xu, Zhiheng; Ji, Ying; Lv, Hua; Jiang, Tianyi; Wang, Wen; Xu, Yunhua; Vercruysse, Maarten; Yao, Xiangyu; Mao, Yi; Yu, Xiaomin; Bradley, Kenneth; Tan, Xuefei. The article conveys some information:

The rise of multidrug resistant (MDR) Gram-neg. (GN) pathogens and the decline of available antibiotics that can effectively treat these severe infections are a major threat to modern medicine. Developing novel antibiotics against MDR GN pathogens is particularly difficult as compounds have to permeate the GN double membrane, which has very different physicochem. properties, and have to circumvent a plethora of resistance mechanisms such as multiple efflux pumps and target modifications. The bacterial type II topoisomerases DNA gyrase (GyrA2B2) and Topoisomerase IV (ParC2E2) are highly conserved targets across all bacterial species and validated in the clinic by the fluoroquinolones. Dual inhibitors targeting the ATPase domains (GyrB/ParE) of type II topoisomerases can overcome target-based fluoroquinolone resistance. However, few ATPase inhibitors are active against GN pathogens. In this study, we demonstrated a successful strategy to convert a 2-carboxamide substituted azaindole chem. scaffold with only Gram-pos. (GP) activity into a novel series with also potent activity against a range of MDR GN pathogens. By systematically fine-tuning the many physicochem. properties, we identified lead compounds such as 17r with a balanced profile showing potent GN activity, high aqueous solubility, and desirable PK features. Moreover, we showed the bactericidal efficacy of 17r using a neutropenic mouse thigh infection model.3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4Safety of 3-(Trifluoromethyl)-1H-pyrazole) was used in this study.

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics